Avalo Therapeutics Inc (AVTX)

Currency in USD
15.750
-0.500(-3.08%)
Closed·
15.7500.000(0.00%)
·
AVTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
15.37016.540
52 wk Range
3.39020.720
Key Statistics
Prev. Close
16.25
Open
16.25
Day's Range
15.37-16.54
52 wk Range
3.39-20.72
Volume
249.62K
Average Volume (3m)
333.69K
1-Year Change
108.8859%
Book Value / Share
6.96
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AVTX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
34.375
Upside
+118.25%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Avalo Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Avalo Therapeutics Inc Company Profile

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Compare AVTX to Peers and Sector

Metrics to compare
AVTX
Peers
Sector
Relationship
P/E Ratio
−2.9x−1.9x−0.6x
PEG Ratio
−0.030.050.00
Price/Book
3.2x2.0x2.6x
Price / LTM Sales
1,518.6x179.6x3.4x
Upside (Analyst Target)
125.4%216.3%41.5%
Fair Value Upside
Unlock4.6%4.4%Unlock

Analyst Ratings

10 Buy
0 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 34.375
(+118.25% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy25.00+58.73%-MaintainJan 15, 2026
Mizuho
Buy39.00+147.62%-New CoverageDec 18, 2025
H.C. Wainwright
Buy25.00+58.73%15.00MaintainSep 18, 2025
Oppenheimer
Buy35.00+122.22%-MaintainSep 18, 2025
TD Cowen
Buy---New CoverageSep 05, 2025

Earnings

Latest Release
Nov 06, 2025
EPS / Forecast
-2.19 / -1.22
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

AVTX Income Statement

People Also Watch

14.7000
TENX
-0.54%
156.21
INSM
-2.61%
122.12
ABVX
-1.22%
480.45
MDGL
-3.53%
15.180
EYPT
-7.07%

FAQ

What Is the Avalo Therapeutics (AVTX) Stock Price Today?

The Avalo Therapeutics stock price today is 15.750

What Stock Exchange Does Avalo Therapeutics Trade On?

Avalo Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Avalo Therapeutics?

The stock symbol for Avalo Therapeutics is "AVTX."

What Is the Avalo Therapeutics Market Cap?

As of today, Avalo Therapeutics market cap is 291.58M.

What Is Avalo Therapeutics's Earnings Per Share (TTM)?

The Avalo Therapeutics EPS (TTM) is -8.74.

From a Technical Analysis Perspective, Is AVTX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Avalo Therapeutics Stock Split?

Avalo Therapeutics has split 2 times.

How Many Employees Does Avalo Therapeutics Have?

Avalo Therapeutics has 23 employees.

What is the current trading status of Avalo Therapeutics (AVTX)?

As of Jan 25, 2026, Avalo Therapeutics (AVTX) is trading at a price of 15.750, with a previous close of 16.250. The stock has fluctuated within a day range of 15.370 to 16.540, while its 52-week range spans from 3.390 to 20.720.

What Is Avalo Therapeutics (AVTX) Price Target According to Analysts?

The average 12-month price target for Avalo Therapeutics is USD34.375, with a high estimate of USD48 and a low estimate of USD24. 10 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +118.25% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.